Targeting small GTPase Cdc42 in aged adipose mesenchymal stem cells for the improvement of effectiveness of cell therapy for bone regeneration

Project: Research project

Grant Program

Collaborative Research Grants Program 2020-2022

Project Description

The purpose of the Project: Rejuvenation of aging adipose mesenchymal stem cells by Cdc42 inhibition for improving the therapeutic effectiveness of bone fracture repair
Accumulating evidences suggest that small Rho GTPase cell division control protein 42 homolog, also known as Cdc42 have a great impact on the pathogenesis of chronic and age-related diseases. Our previous studies have shown that a Cdc42 inhibitor CASIN increased proliferative activity and osteogenic differentiation potential in adipose-derived mesenchymal stem cells (ADMSCs) isolated from 24-month old rats.As a continuation of our previous work related to in vitro Cdc42 research, in the present project we are very interested in evaluating in vivo testing of bone healing induced by the activation of ADMSCs via Cdc42 regulation. We hypothesize that inhibition of aging-associated increase in Cdc42 activity in MSCs in ex-vivo conditions can improve MSC osteogenic differentiation and migration and reduce osteoclastic activity for MSC-based therapy in bone regeneration. We propose that a method based on the use of cell therapy for ADMSCs after ex-vivo inhibition of Cdc42 activity will be an effective approach for stimulating reparative osteogenesis and will improve the results of treatment of pathological bone fractures.
StatusActive
Effective start/end date1/1/2012/31/22

Fingerprint

Bone Regeneration
Monomeric GTP-Binding Proteins
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Bone Fractures
Rejuvenation
rho GTP-Binding Proteins
Spontaneous Fractures
Organized Financing
Research
Osteogenesis
Cell Division
Therapeutics
Bone and Bones
Proteins

Keywords

  • Aging
  • Cdc42
  • Mesenchymal stem cells
  • Bone fracture
  • Cell therapy